Abstract PS9-17: Nurse navigation in the ambulatory oncology clinic: Patient-centered findings from a survey of 50 breast cancer patients

2021 ◽  
Author(s):  
Tianyi Wang ◽  
Yash Huilgol ◽  
Jennifer James ◽  
Jeff Belkora ◽  
Janet Black ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Patient Centered ◽  
Clinic Patient ◽  
Ambulatory Oncology

scholarly journals PCN30 Treatment Patterns and Outcomes of Breast Cancer Patients in a Patient-Centered Retrospective Research Registry

2012 ◽  
Vol 15 (7) ◽  
pp. A414
Author(s):  
S. Saokaew ◽  
B. Cai ◽  
K.L. Kuo ◽  
H. Bauer ◽  
F. Albright ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Treatment Patterns ◽  
Breast Cancer Patients ◽  
Patient Centered

Patient-provider communication during post-treatment breast cancer care: Findings from a pilot project.

2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 91-91 ◽  
Author(s):  
Neetu Chawla ◽  
Michael Sanchez ◽  
Jayson Harpster ◽  
Leslie Manace Brenman ◽  
Raymond Liu
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Pilot Project ◽  
Post Treatment ◽  
Social Needs ◽  
Provider Communication ◽  
Breast Cancer Patients ◽  
Patient Centered ◽  
Treatment Side Effects ◽  
Patient Provider Communication

91 Background: Patient-provider communication is essential to delivering high quality cancer care, including post-treatment when survivors have many complex care needs. In this study, we used data collected for quality improvement from a small, feasibility sample to examine patient perceptions of provider communication and inform the development of a new Oncology Survivorship Clinic model. Methods: As part of a pilot project conducted at Kaiser Permanente Northern California (KPNC), we surveyed 51 breast cancer patients post-treatment. The survey included a communication measure from the 2011 Medical Expenditure Panel Survey (MEPS) Experiences with Cancer survey evaluating provider discussions of: surveillance for recurrence; late or long-term treatment effects; healthy lifestyle behaviors; and emotional or social needs. We also examined reports of the six core functions of patient-centered communication (i.e. managing uncertainty, responding to emotions, making decisions, fostering healing relationships, enabling self-management, and exchanging information) using a measure from the Health Information Trends Survey (HINTS) survey. Part of the purpose was to evaluate acceptability of a new Oncology Survivorship Clinic utilizing non-physician providers. Results: The sample included 51 breast cancer patients surveyed in 2016 within six months of treatment completion. Overall, sizable proportions received detailed communication about surveillance (65%), treatment side effects (46%), emotional needs (41%), and healthy lifestyles (71%) and the majority received patient-centered communication (range: 60-73% based on core function). Particular gaps were noted related to provider communication about treatment side effects (54%), emotional/social needs (59%), managing uncertainty (35%), and responding to emotions (40%). Conclusions: Our very preliminary findings suggest that the majority of women had positive communication experiences, including with non-physician providers. However, clear communications gaps existed underscoring future avenues for research and care delivery interventions to address the comprehensive needs of breast cancer patients.

Patient-centered wait time measurement in Ontario.

2012 ◽  
Vol 30 (34_suppl) ◽  
pp. 233-233 ◽  
Author(s):  
Leonard Kaizer ◽  
Monika Karolina Krzyzanowska ◽  
Sherrie Hertz ◽  
John Srigley ◽  
Julian Dobranowski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Medical Oncology ◽  
Early Stage ◽  
Wait Time ◽  
Breast Cancer Patients ◽  
Patient Centered

233 Background: Since 2005, a concerted effort to measure and manage access to chemotherapy services in Ontario has resulted in a significant reduction in several specific wait time intervals (referral for medical oncology consultation and medical oncology consultation to first treatment). To identify other opportunities to improve access, a comprehensive analysis of the all-inclusive wait times from cancer diagnosis to the start of adjuvant chemotherapy for patients with early stage colon, breast, and lung cancer (patient centered wait time) has been undertaken. Methods: The study cohort comprised all Ontario patients who received adjuvant chemotherapy in 2009 for early stage colon, breast, and lung cancers. The Ontario Cancer Registry, linked to several administrative healthcare databases in Ontario, was used to identify the cohort and variables of interest. Wait time from diagnosis of cancer to the initiation of adjuvant chemotherapy was measured and separated into segments based on the dates of diagnosis (D), surgery (S), referral to medical oncology (R), medical oncology consultation (C), and first adjuvant chemotherapy treatment (T), and each was analyzed for variation at a regional and institutional level. The times from surgery to pathology sign-out (TTPR) and for peripherally inserted central catheter (PICC) acquisition were also studied in a subset of cases. Results: In 2009, 86% of patients with stage III colon cancer, 80% of patients with stage I to III breast cancer and 63% of patients with stage II lung cancer who received adjuvant chemotherapy started their treatment within 120 days of diagnosis. There was significantly better performance and less regional variation for colon cancer patients (82-93%) than for breast cancer patients (63-90%). For the whole cohort of breast cancer patients, the median total time from diagnosis to adjuvant chemotherapy was 81 days with the following segmental breakdown D-S (30 days), S-R (19 days), R-C (16 days), and C-T (16 days). The mean TTPR for colon cancer patients was 11.6 days and PICC insertion was < 7 days in 92% of patients. Conclusions: A number of opportunities for process improvement were identified, including shortening the pathology reporting interval and the timing for initiating referral to a medical oncologist.

A discrete choice experiment to examine preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors (G-CSF) in previously treated breast cancer patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e17509-e17509 ◽  
Author(s):  
Phaedra Johnson ◽  
Tim Bancroft ◽  
Richard L. Barron ◽  
Jason C. Legg ◽  
Xiaoyan Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Willingness To Pay ◽  
Cancer Patients ◽  
Discrete Choice Experiment ◽  
Discrete Choice ◽  
Patient Preferences ◽  
Choice Experiment ◽  
Risk Of Infection ◽  
Breast Cancer Patients ◽  
Patient Centered

e17509 Background: As patient-centered care becomes more prominent, a better understanding of patient preferences and tradeoffs amongst treatment alternatives and outcomes is needed. This study used a discrete choice experiment to examine the preferences and willingness to pay for prophylactic G-CSF to decrease the incidence of chemotherapy (CT)-induced febrile neutropenia in breast cancer patients who previously received CT. Methods: An online survey was developed with 16 paired treatment choice scenarios comparing 3 alternative G-CSF options (11 versus 1 or 6 versus 1 injections per CT cycle) with a follow-up “no treatment” option. Each scenario had 4 attributes: risk of disruption to CT schedule due to neutropenia, risk of infection requiring hospitalization, frequency of G-CSF administration, and total out-of-pocket (OOP) cost for G-CSF during a CT cycle. Patients’ preferences and willingness to pay (as OOP cost) were estimated using logistic regression. Results: Patients’ (n = 296) preferred G-CSF options with the lowest OOP costs, the fewest injections, and improved outcomes (lowest risk of disruption to CT schedule and lowest risk of infection requiring hospitalization). In the context of this discrete choice experiment, OOP costs and risk of disruption to CT schedule were the most important attributes to patients; risk of infection requiring hospitalization and frequency of G-CSF administration affected patients’ choice of G-CSF option to a smaller but similar degree. Patients were willing to pay OOP $1,076 per cycle to reduce the risk of disrupting the CT schedule from high to low, $884 per cycle to reduce the risk of developing an infection requiring hospitalization from 24% (high) to 7% (low), and $851 and $667 per cycle to decrease the number of G-CSF injections per cycle from 11 to 1 and 6 to 1, respectively. Conclusions: With a current focus on patient-centered approaches in decision-making, physicians need to consider patient preferences when making decisions about therapy, including supportive care agents.

scholarly journals Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0244355
Author(s):  
Laura Ciria-Suarez ◽  
Paula Jiménez-Fonseca ◽  
María Palacín-Lois ◽  
Mónica Antoñanzas-Basa ◽  
Ana Férnández-Montes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Survivors ◽  
Structured Interview ◽  
Breast Cancer Patients ◽  
Structured Interviews ◽  
Patient Centered ◽  
Medical Oncologists ◽  
Qualitative Descriptive ◽  
Patients Experience

Background The current cancer care system must be improved if we are to have in-depth knowledge about breast cancer patients’ experiences throughout all the stages of their disease. Aim This study seeks to describe breast cancer patients’ experience over the course of the various stages of illness by means of a journey model. Methods This is a qualitative descriptive study. Individual, semi-structured interviews will be administered to women with breast cancer and breast cancer survivors. Patients will be recruited from nine large hospitals in Spain and intentional sampling will be used. Data will be collected by means of a semi-structured interview that was elaborated with the help of medical oncologists, nurses, and psycho-oncologists. Data will be processed adopting a thematic analysis approach. Discussion The outcomes of this study will afford new insights into breast cancer patients’ experiences, providing guidance to improve the care given to these individuals. This protocol aims to describe the journey of patients with breast cancer through the healthcare system to establish baseline data that will serve as the basis for the development and implementation of a patient-centered, evidence-based clinical pathway.

Sign in / Sign up

Export Citation Format

Share Document